Everolimus Directly Suppresses Insulin Secretion Independently of Cell Growth Inhibition

Everolimus, an orally administered mammalian target of rapamycin inhibitor, has been widely used as an immunosuppressant and an anticancer agent. Whereas everolimus can control recurrent hypoglycemia in patients with insulinoma, possibly through tumor regression and/or the direct inhibition of insul...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Endocr Soc
Huvudupphovsmän: Suzuki, Luka, Miyatsuka, Takeshi, Himuro, Miwa, Nishio, Rie, Goto, Hiromasa, Uchida, Toyoyoshi, Nishida, Yuya, Kanazawa, Akio, Watada, Hirotaka
Materialtyp: Artigo
Språk:Inglês
Publicerad: Endocrine Society 2018
Ämnen:
Brief Report
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6007247/
https://ncbi.nlm.nih.gov/pubmed/29942923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2017-00475
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk